The ethics of aHUS treatment trials
When someone is affected by aHUS, the issue of it being a rare disease soon becomes apparent. The injustices felt by…
aHUS Drug Candidates – the 2022 Landscape
What’s new in 2022 regarding expansion in atypical HUS knowledge, and advancements for investigational drugs which may have potential as new…
Atypical HUS: Listen, Comprehend, Act
It’s been quite an unsettling end to the first half of 2022 within the atypical HUS community, as July 2022 has…
What became of the aHUS 130?
Article No. 446 14 July 2021 Eculizumab effectiveness and safety in the treatment of aHUS was established in five clinical trials…
aHUS uncertainty is a certainty
Article No. 423 16 March 2021 Update: Seven days after this news blog was published a further report on the ravulizumab…
Breaking Down Barriers in aHUS Clinical Trials
Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.
aHUS and TMA Study Centers
aHUS and TMA Study Centers An International List Compiled by the aHUS Alliance Atypical HUS is difficult…
Dr Ralf Reski on Moss-Made Biopharmaceuticals: aHUS Alliance Interview
The aHUS Alliance recently conducted an interview with Dr Ralf Reski, a professor and researcher in the field of…
aHUS Trials Watch 5
An update on STOPECU ( NCT02574403) -the French Study of the withdrawal from eculizumab treatment which began in late 2015. ( click…